ERBB2 and inflammatory breast carcinoma: Although improvements in IBC patient survival have been noted with the introduction of trastuzumab-based systemic therapy to treat patients with the HER2-expressing subtype [21, 24–29], this improved outcome is not seen in the triple-negative IBC group, who are excluded from hormonal therapy and HER2 targeting as treatment options [30–31].